Deals Of The Week: Novartis/Adimab, Novartis/Alcon/LenSx, Biovitrum/Dongbao, Infinity/Intellikine
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Infinity In-Licenses Portfolio Of PI3 Kinase Inhibitors For Inflammatory Diseases
Deal is the historically oncology-focused Infinity's first pipeline-building move since it began a strategic alliance with Purdue Pharma and the latter's European affiliate Mundipharma in late 2008.
Alcon Shareholders Reject "Inadequate" Novartis Offer
When Novartis announced on Jan. 4 its intention to not only exercise its option to purchase Nestle's remaining 52 percent stake in eye-care group Alcon, but also to buy out the remaining, minority-held 23 percent, CEO and Chairman Daniel Vasella claimed this second step would "create clarity for all stakeholders
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011